Since the third quarter, investment and financing in the field of medical equipment have been hot, and the financing scale of some enterprises has exceeded 5 billion yuan

【Pharmaceutical Network Industry News】How is the investment and financing of medical devices? According to iFinD data, since July this year (as of October 23), a total of 514 financing events have occurred in the biomedical industry, with a total investment of 107.
591 billion yuan
.
Among them, the investment and financing of medical devices in subdivided fields is hot, and the financing scale ranges
from tens of millions of yuan to billions of yuan.
There is a new round of financing for medical device companies with a scale of more than 5 billion yuan, from United Imaging Medical, which occurred in August this year, with a financing scale of 5.
494 billion yuan
.
It is reported that United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions
.
The company is headquartered in Shanghai, and has set up regional headquarters and R&D centers in the United States, Malaysia, the United Arab Emirates, Poland and other places, and has established a global R&D, production and service network
in Shanghai, Changzhou, Wuhan and Houston.
In addition to the large-scale financing that occurred in August, United Imaging Medical is backed by state-owned assets
.
As early as September 2017, United Imaging Medical completed a series A financing with a financing scale of 3.
333 billion yuan, which was jointly led by Chinese Life Health Fund and SDIC Innovation Investment Management Co.

, Ltd 。 It was followed by the ophthalmic specialty medical chain enterprise Aier Ophthalmology, which announced in October that the plan to increase the fixed increase of 3.
536 billion yuan was officially landed, mainly used for Changsha Aier relocation and expansion project, Hubei Aier new project, Anhui Aier new project, Shenyang Aier relocation and expansion project, Shanghai Aier relocation and expansion project, Guizhou Aier new construction project, Nanning Aier relocation and expansion project, of which 891 million yuan is used to supplement working capital
。 Not only United Imaging Medical, Aier Ophthalmology, but also medical equipment companies including Wuzhou Medical, MicroPort Brain Science, Weimai Medical, Hanno Medical, Shensi Medical, Runmed and other medical equipment companies have obtained new financing
since the third quarter.
Behind the capital entering the field of medical equipment, it can be seen that it is optimistic about its prospects
.
In fact, the medical equipment industry has been supported by a series of favorable policies since the second half of the year, and with the continuous deepening of new medical infrastructure, many securities companies believe that the allocation value of the track is prominent
.
The industry was worried that the "soul bargaining" of collective procurement may lead to a decline in the gross profit margin of enterprises, but from the current situation, the overall decline is relatively moderate, and there are more
opportunities for domestic substitution.
On October 14, Fujian Provincial Joint Procurement Center for Pharmaceuticals and Devices issued an announcement "Laparoscopic Cutting Kiss/Suture Instrument Medical Consumables Inter-provincial Alliance Centralized Procurement Announcement (No.
1)", the overall price reduction is relatively moderate, import manufacturers are expected to report the volume to be seized by domestic manufacturers, domestic substitution is expected to accelerate
.
On the same day, Fujian Provincial Joint Procurement Center for Pharmaceuticals and Devices issued an announcement "Announcement on the Centralized Procurement of Inter-provincial Alliance of Cardiac Interventional Electrophysiology Medical Consumables"
.
The selection rules of this electrophysiological centralized procurement policy are relatively soft
.
Kaiyuan Securities believes that this centralized procurement set and supporting procurement are relatively considering importers, and the single purchase of some products of domestic manufacturers has a relative cost advantage, which is expected to gain more share, while leaving the window time for domestic enterprises to launch innovative products; The highest effective declared price of the electrophysiological consumables involved is close to or slightly higher than the current market price, and there is still a large space for domestic output plant prices; Since many provinces and regions of domestic manufacturers did not have a charging catalogue in the past, which hindered product sales and promotion, centralized procurement will accelerate market access and coverage of domestic manufacturers; The overall 3D electrophysiological surgery will be reduced, and under the DRG/DIP policy, domestic manufacturers are expected to obtain more 3D surgery volume and accelerate the acquisition
of share.
Deppon Securities said that in 2020, the global medical equipment market size will reach 100 billion US dollars, and the global market space will be as high as 200 billion US dollars in 2030.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.